Keiji Sugiyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Keiji Sugiyama has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Chiyoe Kitagawa
Department of Medical Oncology, NHO Nagoya Medical Center, Aichi, Japan
7 shared publicationsKazuhiro Shiraishi
Department of Medical Oncology, NHO Nagoya Medical Center, Aichi, Japan
6 shared publicationsKyoko Kato
Department of Medical Oncology, NHO Nagoya Medical Center, Aichi, Japan
6 shared publicationsMariko Sato
Department of Medical Oncology, NHO Nagoya Medical Center, Aichi, Japan
5 shared publicationsMasaaki Shimada
Department of Gastroenterology, NHO Nagoya Medical Center, Aichi, Japan
4 shared publicationsMasaya Suenaga
Department of Surgery, NHO Nagoya Medical Center, Aichi, Japan
4 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Sex-based survival differences in patients with untreated advanced oesophageal squamous cell carcinoma receiving chemotherapy and immune checkpoint inhibitors: a meta-analysis
- 3 August 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Open AccessSex-based survival differences in patients with untreated advanced oesophageal squamous cell carcinoma receiving chemotherapy and immune checkpoint inhibitors: a meta-analysis
- Open Access
- 30 June 2026
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 40  (4) , 2289-2299
Nutritional Support for Treatment Continuity and Survival in Advanced Gastric Cancer: A Propensity Score-matched Study
This study aimed to clarify the effect of nutritional support in patients with advanced gastric cancer (AGC) receiving first-line chemotherapy. We retrospectively reviewed the medical records of consecutive patients with unresectable or recurrent AGC treated with first-line chemotherapy at Nagoya Medical Center between 2007 and 2024. Patients who received nutritional support were compared with those without nutritional support. Nutritional support included individualized dietary counselling, assessment of energy and protein requirements, and multidisciplinary evaluation. Propensity score matching (PSM, 1:1) was applied to adjust for baseline nutritional and inflammatory status. The primary endpoint was time to treatment failure (TTF). Subgroup analyses were conducted by baseline albumin level. Among the 324 eligible patients included in the analysis, 76 received nutritional support. Before PSM, patients who were provided nutritional support more frequently presented with poor nutritional profiles. After PSM (n=46 per group), the median TTF was 5.0 months in patients without nutritional support and 4.6 months in those with it. In patients with hypoalbuminemia (albumin <3.5 g/dl), nutritional support significantly prolonged TTF. Finally, multivariate analysis in the pre-PSM cohort identified nutritional support as an independent predictor of TTF. Although nutritional support was not associated with significant TTF improvement in the overall AGC population after propensity score matching, it emerged as an independent predictor of treatment continuity in multivariate analysis of the pre-PSM cohort. This benefit was particularly evident in patients with hypoalbuminemia, indicating that targeted nutritional intervention is essential for this vulnerable subgroup to prevent premature treatment failure.
- 30 June 2026
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 40  (4) , 2289-2299
Open AccessNutritional Support for Treatment Continuity and Survival in Advanced Gastric Cancer: A Propensity Score-matched Study
This study aimed to clarify the effect of nutritional support in patients with advanced gastric cancer (AGC) receiving first-line chemotherapy. We retrospectively reviewed the medical records of consecutive patients with unresectable or recurrent AGC treated with first-line chemotherapy at Nagoya Medical Center between 2007 and 2024. Patients who received nutritional support were compared with those without nutritional support. Nutritional support included individualized dietary counselling, assessment of energy and protein requirements, and multidisciplinary evaluation. Propensity score matching (PSM, 1:1) was applied to adjust for baseline nutritional and inflammatory status. The primary endpoint was time to treatment failure (TTF). Subgroup analyses were conducted by baseline albumin level. Among the 324 eligible patients included in the analysis, 76 received nutritional support. Before PSM, patients who were provided nutritional support more frequently presented with poor nutritional profiles. After PSM (n=46 per group), the median TTF was 5.0 months in patients without nutritional support and 4.6 months in those with it. In patients with hypoalbuminemia (albumin <3.5 g/dl), nutritional support significantly prolonged TTF. Finally, multivariate analysis in the pre-PSM cohort identified nutritional support as an independent predictor of TTF. Although nutritional support was not associated with significant TTF improvement in the overall AGC population after propensity score matching, it emerged as an independent predictor of treatment continuity in multivariate analysis of the pre-PSM cohort. This benefit was particularly evident in patients with hypoalbuminemia, indicating that targeted nutritional intervention is essential for this vulnerable subgroup to prevent premature treatment failure.
- Open Access
- 18 June 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Improvement of survival in advanced gastric cancer over 15 years: real-world analysis by 5-year periods
- 18 June 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Open AccessImprovement of survival in advanced gastric cancer over 15 years: real-world analysis by 5-year periods
- 27 May 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46  (6) , 3431-3440
Clinical Outcomes in Advanced Gastric Cancer Among Patients Aged ≥80 Years Treated With Chemotherapy
The proportion of older patients with advanced gastric cancer (AGC) is increasing, yet evidence regarding the clinical impact of very advanced age (≥80 years) on systemic chemotherapy efficacy and safety remains limited. This study evaluated real-world treatment patterns and outcomes across age groups and assessed the prognostic significance of advanced age in patients with AGC. Patients with unresectable or recurrent gastric or gastroesophageal junction adenocarcinomas who received first-line systemic chemotherapy between 2009 and 2024 were included through a retrospective chart review and stratified into three age groups: <70, 70-79, and ≥80 years old. Overall survival (OS) was the primary endpoint; secondary endpoints included time-to-treatment failure (TTF), objective response rate (ORR), and disease control rate (DCR). In total, 322 patients were included. The median OS, TTF, ORR, and DCR did not differ significantly across age groups. Although age ≥80 years was associated with worse OS in univariate analysis, it was not an independent prognostic factor. Patients aged ≥80 years received fewer subsequent treatment lines and more frequently discontinued first-line therapy because of toxicity. Advanced age was not an independent prognostic factor in AGC. Despite reduced treatment continuity and higher toxicity-related discontinuation in patients of advanced age, antitumor activity was similar across all age groups, supporting the use of systemic chemotherapy with careful patient selection and toxicity monitoring.
- 27 May 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46  (6) , 3431-3440
Clinical Outcomes in Advanced Gastric Cancer Among Patients Aged ≥80 Years Treated With Chemotherapy
The proportion of older patients with advanced gastric cancer (AGC) is increasing, yet evidence regarding the clinical impact of very advanced age (≥80 years) on systemic chemotherapy efficacy and safety remains limited. This study evaluated real-world treatment patterns and outcomes across age groups and assessed the prognostic significance of advanced age in patients with AGC. Patients with unresectable or recurrent gastric or gastroesophageal junction adenocarcinomas who received first-line systemic chemotherapy between 2009 and 2024 were included through a retrospective chart review and stratified into three age groups: <70, 70-79, and ≥80 years old. Overall survival (OS) was the primary endpoint; secondary endpoints included time-to-treatment failure (TTF), objective response rate (ORR), and disease control rate (DCR). In total, 322 patients were included. The median OS, TTF, ORR, and DCR did not differ significantly across age groups. Although age ≥80 years was associated with worse OS in univariate analysis, it was not an independent prognostic factor. Patients aged ≥80 years received fewer subsequent treatment lines and more frequently discontinued first-line therapy because of toxicity. Advanced age was not an independent prognostic factor in AGC. Despite reduced treatment continuity and higher toxicity-related discontinuation in patients of advanced age, antitumor activity was similar across all age groups, supporting the use of systemic chemotherapy with careful patient selection and toxicity monitoring.
- Open Access
- 29 October 2025
- Published by MDPI AG in Current Oncology
- Vol. 32  (11) , 604
New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies
Growth differentiation factor 15 (GDF-15) is a stress-induced cytokine produced by tumour cells and peripheral cells. It is implicated in the development of cancer cachexia, a debilitating condition for which no effective pharmacological therapy currently exists. GDF-15 regulates appetite and metabolic processes through complex neural and hormonal networks. Furthermore, it has been implicated in chemotherapy-induced nausea and vomiting, representing a potential therapeutic target. GDF-15 negatively affects tumour immunity, suggesting that anti-GDF-15 therapy could potentially enhance immune responses and help overcome resistance to immunotherapy. Recently, early clinical trials have reported preliminary results of GDF-15-targeted therapies in alleviating cancer cachexia and potentially enhancing the efficacy of immunotherapy. This review aims to provide an overview of the role of GDF-15 in cancer cachexia, including the underlying neural mechanisms and their involvement in tumour immunity. This review also summarises recent clinical trial findings and discusses future perspectives on GDF-15-targeted therapy in oncology, offering important insights for future research.
- 29 October 2025
- Published by MDPI AG in Current Oncology
- Vol. 32  (11) , 604
Open AccessNew Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies
Growth differentiation factor 15 (GDF-15) is a stress-induced cytokine produced by tumour cells and peripheral cells. It is implicated in the development of cancer cachexia, a debilitating condition for which no effective pharmacological therapy currently exists. GDF-15 regulates appetite and metabolic processes through complex neural and hormonal networks. Furthermore, it has been implicated in chemotherapy-induced nausea and vomiting, representing a potential therapeutic target. GDF-15 negatively affects tumour immunity, suggesting that anti-GDF-15 therapy could potentially enhance immune responses and help overcome resistance to immunotherapy. Recently, early clinical trials have reported preliminary results of GDF-15-targeted therapies in alleviating cancer cachexia and potentially enhancing the efficacy of immunotherapy. This review aims to provide an overview of the role of GDF-15 in cancer cachexia, including the underlying neural mechanisms and their involvement in tumour immunity. This review also summarises recent clinical trial findings and discusses future perspectives on GDF-15-targeted therapy in oncology, offering important insights for future research.
- 8 May 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21  (14) , 1753-1759
A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS)
Combination treatment with an anti-programmed cell death-1 (PD-1) antibody, an immune checkpoint inhibitor (ICI), and chemotherapy is the standard treatment for patients with HER2-negative advanced gastric/esophagogastric cancer (AGC). ICI re-administration has been reported to have a clinical benefit for patients with lung cancer or melanoma. However, data on patients with AGC have not yet been collected. We plan to conduct a prospective, multicenter, observational NIVO RETURNS study to evaluate the efficacy and safety of nivolumab monotherapy re-administration in patients with AGC refractory to initial anti-PD-1 or anti-programmed cell death ligand-1 (PD-L1) antibody treatment. Patients who have achieved clinical benefits (complete response, partial response, or stable disease for ≥ 6 months) from prior treatment, including anti-PD-1/PD-L1 therapy, will be included. The primary endpoint will be the objective response rate to nivolumab re-administration. We anticipate that our findings will contribute to the improvement of survival outcomes as later-line treatment for AGC.Clinical trial registration: UMIN000050515, UMIN000051044.
- 8 May 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21  (14) , 1753-1759
A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS)
Combination treatment with an anti-programmed cell death-1 (PD-1) antibody, an immune checkpoint inhibitor (ICI), and chemotherapy is the standard treatment for patients with HER2-negative advanced gastric/esophagogastric cancer (AGC). ICI re-administration has been reported to have a clinical benefit for patients with lung cancer or melanoma. However, data on patients with AGC have not yet been collected. We plan to conduct a prospective, multicenter, observational NIVO RETURNS study to evaluate the efficacy and safety of nivolumab monotherapy re-administration in patients with AGC refractory to initial anti-PD-1 or anti-programmed cell death ligand-1 (PD-L1) antibody treatment. Patients who have achieved clinical benefits (complete response, partial response, or stable disease for ≥ 6 months) from prior treatment, including anti-PD-1/PD-L1 therapy, will be included. The primary endpoint will be the objective response rate to nivolumab re-administration. We anticipate that our findings will contribute to the improvement of survival outcomes as later-line treatment for AGC.Clinical trial registration: UMIN000050515, UMIN000051044.
- Open Access
- 17 January 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 133, 102888
Claudins as diagnostic tools and therapeutic targets—Glimpse of the horizon
- 17 January 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 133, 102888
Open AccessClaudins as diagnostic tools and therapeutic targets—Glimpse of the horizon
- Open Access
- 25 December 2023
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 38  (1) , 518-522
Immunotherapy for Unresectable Small Bowel Adenocarcinoma: A Case Series
Background/Aim: The efficacy of systemic therapy for unresectable small bowel adenocarcinoma that is refractory to fluoropyrimidines and oxaliplatin has not yet been established because of the rarity of this cancer. Although immunotherapy with anti-PD-1 antibodies has shown robust efficacy in the treatment of esophagogastric adenocarcinoma, its effectiveness in small bowel adenocarcinoma remains unclear. Case Report: In the first case, a 75-year-old man was diagnosed with metastatic moderately differentiated adenocarcinoma of the jejunum with stable microsatellite instability. After receiving multiple lines of therapy, including fluoropyrimidines plus oxaliplatin, irinotecan, and paclitaxel, the patient was treated with nivolumab and achieved a partial response that lasted for 12 months. In the second case, a 65-year-old man was diagnosed with an unresectable locally advanced duodenal adenocarcinoma. High microsatellite instability was confirmed by polymerase chain reaction-based testing. After showing resistance to 5-fluorouracil and oxaliplatin, the patient received nivolumab and ipilimumab therapy. Although therapy was discontinued because of immune-related colitis and skin rash, a partial response was achieved. Conclusion: Treatment with immune checkpoint inhibitors is effective for refractory small bowel adenocarcinoma, irrespective of the microsatellite status.
- 25 December 2023
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 38  (1) , 518-522
Open AccessImmunotherapy for Unresectable Small Bowel Adenocarcinoma: A Case Series
Background/Aim: The efficacy of systemic therapy for unresectable small bowel adenocarcinoma that is refractory to fluoropyrimidines and oxaliplatin has not yet been established because of the rarity of this cancer. Although immunotherapy with anti-PD-1 antibodies has shown robust efficacy in the treatment of esophagogastric adenocarcinoma, its effectiveness in small bowel adenocarcinoma remains unclear. Case Report: In the first case, a 75-year-old man was diagnosed with metastatic moderately differentiated adenocarcinoma of the jejunum with stable microsatellite instability. After receiving multiple lines of therapy, including fluoropyrimidines plus oxaliplatin, irinotecan, and paclitaxel, the patient was treated with nivolumab and achieved a partial response that lasted for 12 months. In the second case, a 65-year-old man was diagnosed with an unresectable locally advanced duodenal adenocarcinoma. High microsatellite instability was confirmed by polymerase chain reaction-based testing. After showing resistance to 5-fluorouracil and oxaliplatin, the patient received nivolumab and ipilimumab therapy. Although therapy was discontinued because of immune-related colitis and skin rash, a partial response was achieved. Conclusion: Treatment with immune checkpoint inhibitors is effective for refractory small bowel adenocarcinoma, irrespective of the microsatellite status.
- Open Access
- 2 January 2023
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 75  (3) , 867-875
The Impact of Nutritional Support on Survival Outcomes in Patients with Advanced Gastric Adenocarcinoma Treated with Chemotherapy
Malnutrition and cachexia occur commonly in patients with advanced gastric cancer (AGC). This study elucidated the effect of nutritional support (NS) on survival outcomes among patients with AGC undergoing chemotherapy. We retrospectively evaluated new AGC cases at our institute between January 2015 and January 2021. Inclusion criteria were unresectable or recurrent chemotherapy-treated gastric adenocarcinoma, ECOG performance status (PS) 0–2, and adequate organ function. Time to treatment failure (TTF) and overall survival (OS) were evaluated, and univariate and multivariate analyses identified prognostic factors. A total of 103 eligible patients were separated into groups: 69 patients (67%) into NS and 34 (33%) into routine care (RC). The median follow-up time was 11.0 mo, (0.5–92). NS was offered to patients with poorer PS (p = 0.03), Glasgow prognostic score (GPS) positivity (p = 0.001), and high neutrophil-to-lymphocyte ratios (cut-off ≤ 3, p = 0.02). Median OS and TTF in the RC and NS groups were 11.6 and 10.4 mo, (p = 0.99) and 4.2 and 5.5 mo, (p = 0.07), respectively. Multivariate analyses identified NS (hazard ratio [HR] = 0.53, p = 0.01) and GPS positivity for TTF, and low body mass index (HR = 2.03, p = 0.007) and GPS positivity (HR = 2.25, p = 0.001) for OS as significant prognostic factors. Thus, NS with chemotherapy is a potentially effective intervention for AGC.
- 2 January 2023
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 75  (3) , 867-875
Open AccessThe Impact of Nutritional Support on Survival Outcomes in Patients with Advanced Gastric Adenocarcinoma Treated with Chemotherapy
Malnutrition and cachexia occur commonly in patients with advanced gastric cancer (AGC). This study elucidated the effect of nutritional support (NS) on survival outcomes among patients with AGC undergoing chemotherapy. We retrospectively evaluated new AGC cases at our institute between January 2015 and January 2021. Inclusion criteria were unresectable or recurrent chemotherapy-treated gastric adenocarcinoma, ECOG performance status (PS) 0–2, and adequate organ function. Time to treatment failure (TTF) and overall survival (OS) were evaluated, and univariate and multivariate analyses identified prognostic factors. A total of 103 eligible patients were separated into groups: 69 patients (67%) into NS and 34 (33%) into routine care (RC). The median follow-up time was 11.0 mo, (0.5–92). NS was offered to patients with poorer PS (p = 0.03), Glasgow prognostic score (GPS) positivity (p = 0.001), and high neutrophil-to-lymphocyte ratios (cut-off ≤ 3, p = 0.02). Median OS and TTF in the RC and NS groups were 11.6 and 10.4 mo, (p = 0.99) and 4.2 and 5.5 mo, (p = 0.07), respectively. Multivariate analyses identified NS (hazard ratio [HR] = 0.53, p = 0.01) and GPS positivity for TTF, and low body mass index (HR = 2.03, p = 0.007) and GPS positivity (HR = 2.25, p = 0.001) for OS as significant prognostic factors. Thus, NS with chemotherapy is a potentially effective intervention for AGC.